WEKO3
アイテム
悪性卵巣腫瘍治療の現況と展望
http://hdl.handle.net/10191/42311
http://hdl.handle.net/10191/4231122997976-9304-45b5-93c3-d4ad434ec13f
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
109(4)_149-154.pdf (939.2 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-06-27 | |||||
| タイトル | ||||||
| タイトル | 悪性卵巣腫瘍治療の現況と展望 | |||||
| タイトル | ||||||
| タイトル | 悪性卵巣腫瘍治療の現況と展望 | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | ovarian cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | prognostic factor | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | tumor-infiltrating lymphocytes (TIL) | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 卵巣癌 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 予後因子 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | 養子免疫療法 | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| その他のタイトル | ||||||
| その他のタイトル | Current Status and Prospects of Therapy for Malignant Ovarian Tumour | |||||
| 著者 |
児玉, 省二
× 児玉, 省二 |
|||||
| 著者別名 | ||||||
| 識別子Scheme | WEKO | |||||
| 識別子 | 116737 | |||||
| 姓名 | Kodama, Shoji | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | From January 1983 through December 1991, 320 patients with epithelial ovarian cancer were treated at 4 institutions including our hospital. The patients were analyzed as to their condition and treatment method such as FIGO stage, tumor type, type of surgery, and diameter of residual tumor at second look operation (SLO). The breakdown of the patients regarding clinical stage was 33.8 % in stage I, 15.3 % in stage II, 40.0 % in stage III and 10.9 % in stage IV. The rate of complete removal in initial surgery was 99.1 % in stage I, 73.5 % in stage II, 12.5 % in stage III and 11.4 % in stage IV. Sixty six percent of patients in stage III and stage IV had unresectable tumors of more than 2 cm in diameter. SLO reveraled persistnt or recurrent tumor in 1.4 % of stage I, 16.7 % of stage II, 18.2 % of stage III and 66.7 9% of stage IV. Prognosis was also analyzed acording to prognostic clinical characteristics. The 5-year survival rate was 93.0 % in stage I, 70.4 % in stage II, 30.5 % in stage III and 9.5 % in stage IV. The overall survival rate was 54.2 %. The patients who had undergone SLO with complete removal at the initial operatin had better prognosis than those who had not. The 5-year survival rate of those with and without SLO was 97.1 % v.s. 91.2 % in stage I, 75.5 % v.s. 53.0 % in stage II, and 85.7 % v.s. 80.0 % in stage III. Recent combined treatment using of tumor-infiltrating lymphocytes (TIL) and cisplatin-containing chemotherapy showed better prognosis than chemotherapy alone ; survival rate was 83.7 % v.s. 27.3 % (p<0.05). The result suggests that this combination therapy may be hopefull for advanced ovarian cancer. | |||||
| 書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 109, 号 4, p. 149-154, 発行日 1995-04 |
|||||
| 出版者 | ||||||
| 出版者 | 新潟医学会 | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 00290440 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN00182415 | |||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
